

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

POLL RESULTS OF ANNUAL GENERAL MEETING
HELD ON 31 MAY 2019

The Board is pleased to announce that all of the resolutions proposed at the AGM held on 31 May 2019 were duly passed by the Shareholders by way of poll.

The board of directors (the “**Board**”) of China Traditional Chinese Medicine Holdings Co. Limited is pleased to announce that all of the resolutions proposed at the AGM held on 31 May 2019 were duly passed by the Shareholders by way of poll. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular of the Company dated 30 April 2019.

Computershare Hong Kong Investor Services Limited, the share registrar of the Company, was appointed as the scrutineer for the purpose of counting the votes at the AGM.

As at the date of the AGM, there were a total of 5,035,801,852 Shares in issue, which was the total number of Shares entitling the Shareholders to attend and vote on the resolutions at the AGM. To the best of the Directors’ knowledge, information and belief, no Shareholders were required under the Listing Rules to abstain from voting on the resolutions at the AGM. There were no Shares entitling the holders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Listing Rules.

The poll results in respect of the resolutions were as follows:

Ordinary Resolutions			For	Against	Total no. of votes cast
1.	To receive and consider the audited financial statements, the report of the directors and the independent auditor's report for the year ended 31 December 2018.		3,546,642,069 (100.00%)	0 (0.00%)	3,546,642,069
2.	To declare a final dividend of HK5.51 cents per share for the year ended 31 December 2018.		3,546,242,069 (99.97%)	1,186,000 (0.03%)	3,547,428,069
3.	(a)	(1) To re-elect Mr. WU Xian as a director of the Company.	3,316,024,028 (93.51%)	230,218,041 (6.49%)	3,546,242,069
		(2) To re-elect Mr. WANG Xiaochun as a director of the Company.	3,495,638,500 (98.57%)	50,603,569 (1.43%)	3,546,242,069
		(3) To re-elect Mr. YANG Wenming as a director of the Company.	3,119,912,068 (87.98%)	426,330,001 (12.02%)	3,546,242,069
		(4) To re-elect Mr. YANG Shanhua as a director of the Company.	3,048,603,573 (85.97%)	497,638,496 (14.03%)	3,546,242,069
		(5) To re-elect Ms. LI Ru as a director of the Company.	3,080,851,321 (86.88%)	465,390,748 (13.12%)	3,546,242,069
		(6) To re-elect Mr. YANG Binghua as a director of the Company.	3,081,805,321 (86.90%)	464,436,748 (13.10%)	3,546,242,069
		(7) To re-elect Mr. WANG Kan as a director of the Company.	3,080,851,321 (86.88%)	465,390,748 (13.12%)	3,546,242,069
		(8) To re-elect Mr. KUI Kaipin as a director of the Company.	3,081,805,321 (86.90%)	464,436,748 (13.10%)	3,546,242,069
		(9) To re-elect Mr. XIE Rong as a director of the Company.	3,492,124,760 (98.47%)	54,117,309 (1.53%)	3,546,242,069
		(10) To re-elect Mr. QIN Ling as a director of the Company.	2,995,355,255 (84.47%)	550,886,814 (15.53%)	3,546,242,069
		(11) To re-elect Mr. LI Weidong as a director of the Company.	2,973,220,614 (83.84%)	573,021,455 (16.16%)	3,546,242,069
	(b)	To authorize the board of directors of the Company to fix the directors' remuneration.	3,543,425,544 (99.93%)	2,432,525 (0.07%)	3,545,858,069

4.	To re-appoint Deloitte Touche Tohmatsu as the auditors of the Company and authorize the board of directors of the Company to fix their remuneration.	3,512,957,263 (99.06%)	33,284,806 (0.94%)	3,546,242,069
----	--	---------------------------	-----------------------	---------------

As more than 50% of the votes were cast in favour of each of the resolutions, all of the resolutions proposed at the AGM were duly passed as ordinary resolutions of the Company.

Clarification on the payment of final dividend

Reference is made to the English versions of the Circular and the AGM Notice. The Board would like to clarify that the amount of final dividend payable per Share as stated in note 3 of p.18 of the Circular and note 3 to the AGM Notice should be “HK\$5.51 cents (approximately RMB4.71 cents)” (instead of “HK\$5.57 cents (approximately RMB4.71 cents)”).

Save for the above, all other information of the Circular and the AGM Notice (both English version and Chinese version) remains unchanged.

To ascertain the Shareholders’ entitlement to the proposed final dividend, the register of members of the Company will be closed from Tuesday, 11 June 2019 to Thursday, 13 June 2019, both days inclusive, during which period no transfer of Shares will be registered. The final dividend is expected to payable on 28 June 2019 to the Shareholders on the register of members of the Company on 13 June 2019.

By Order of the Board
China Traditional Chinese Medicine Holdings Co. Limited
WU Xian
Chairman

Hong Kong, 31 May 2019

As at the date of this announcement, the Board comprises twelve Directors, of which Mr. WU Xian, Mr. WANG Xiaochun and Mr. YANG Wenming are executive Directors; Mr. YANG Shanhua, Ms. LI Ru, Mr. YANG Binghua, Mr. WANG Kan and Mr. KUI Kaipin are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.